Show simple item record

dc.contributor.authorBukhari, Wajih
dc.contributor.authorKhalilidehkordi, Elham
dc.contributor.authorMason, Deborah F
dc.contributor.authorBarnett, Michael H
dc.contributor.authorTaylor, Bruce V
dc.contributor.authorFabis-Pedrini, Marzena
dc.contributor.authorKermode, Allan G
dc.contributor.authorSubramanian, Sankar
dc.contributor.authorWaters, Patrick
dc.contributor.authorBroadley, Simon A
dc.contributor.authorAustralian and New Zealand NMO Collaboration
dc.date.accessioned2021-07-08T05:07:24Z
dc.date.available2021-07-08T05:07:24Z
dc.date.issued2021
dc.identifier.issn0340-5354
dc.identifier.doi10.1007/s00415-021-10665-9
dc.identifier.urihttp://hdl.handle.net/10072/405844
dc.description.abstractBACKGROUND: We studied the prevalence of neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) in Indigenous populations of Australia and New Zealand with the aim of assessing potential differences. METHODS: Cases of possible NMOSD and MS were collected from Australia and New Zealand. Clinical details, MR imaging, and serologic results were used to apply 2015 IPND diagnostic criteria for NMOSD and 2010 McDonald criteria for MS. Frequencies of self-determined ethnic ancestry were calculated for confirmed NMOSD, suspected NMOSD, and MS. Prevalence rates for NMOSD and MS according to ancestry were compared. RESULTS: There were 75 cases with NMOSD, 89 with suspected NMSOD, and 101 with MS. NMOSD cases were more likely to have Asian, Indigenous, or Other ancestry compared to suspected NMOSD or MS. There were no differences in the clinical phenotype of NMOSD seen in Indigenous compared to European ancestry populations. Per 100,000, the prevalence estimate for NMOSD in people with Māori ancestry was 1.50 (95% CI 0.52-2.49) which was similar to those with Asian ancestry 1.57 (95% CI 1.15-1.98). NMOSD prevalence in Australian Aboriginal and Torres Strait Islander populations was 0.38 (95% CI 0.00-0.80) per 100,000. CONCLUSION: The prevalence of NMOSD in the Māori population is similar to South East Asian countries, reflecting their historical origins. The prevalence of MS in this group is intermediate between those with South East Asian and European ancestry living in New Zealand. Both NMOSD and particularly MS appear to be uncommon in the Indigenous populations of Australia.
dc.description.peerreviewedYes
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.ispartofjournalJournal of Neurology
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchNeurosciences
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode3209
dc.subject.keywordsAboriginal and Torres Strait Islander
dc.subject.keywordsAquaporin
dc.subject.keywordsGenetics
dc.subject.keywordsMāori
dc.subject.keywordsNeuromyelitis optica
dc.titleNMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationBukhari, W; Khalilidehkordi, E; Mason, DF; Barnett, MH; Taylor, BV; Fabis-Pedrini, M; Kermode, AG; Subramanian, S; Waters, P; Broadley, SA; Australian and New Zealand NMO Collaboration, , NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand, Journal of Neurology, 2021
dcterms.dateAccepted2021-06-14
dc.date.updated2021-07-08T01:40:22Z
gro.description.notepublicThis publication has been entered as an advanced online version in Griffith Research Online.
gro.hasfulltextNo Full Text
gro.griffith.authorBroadley, Simon


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record